Fibromyalgia (FM) is a soft tissue pain syndrome that has been estimated to affect 4% of the U.S. population. Precursor terms such as “neurasthenia” and “fibrosi-tis” were used as early as the nineteenth century. The controversy about whether FM is a disorder of the mind or of the body still rages. The American College of Rheumatology (ACR) criteria for the classification of FM include a history of chronic, widespread body pain and at least 11 of 18 designated tender points on physical examination. Patients with FM often have a variety of nonspecific complaints. As examples, fatigue, paresthesias, irritable bowel complaints, subjective swelling of the hands and feet, sleep disturbances, migraine headaches, and deficits of attention and memory are reported commonly in FM. Exercise is a critical part of therapy for FM.


Obstructive Sleep Apnea Irritable Bowel Syndrome Chronic Fatigue Syndrome Tender Point Chronic Widespread Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aaron LA, et al Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness [see comments]. Arthritis Rheum. 1996;39:436–45PubMedCrossRefGoogle Scholar
  2. Annemans L, Wessely S, Spaepen E, et al Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58:895–902PubMedCrossRefGoogle Scholar
  3. Arnold LM, et al A double-blind, multicenter trial comparing dulox-etine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004a;50: 2974–84CrossRefGoogle Scholar
  4. Arnold LM, et al A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191–7PubMedCrossRefGoogle Scholar
  5. Arnold LM, et al Family study of fibromyalgia. Arthritis Rheum. 2004b;50:944–52CrossRefGoogle Scholar
  6. Bondy B, et al The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999; 6: 433–439PubMedCrossRefGoogle Scholar
  7. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol. 1994;21:1113–7PubMedGoogle Scholar
  8. Busch AJ, Barber KA, Overend TJ, et al Exercise for treating fibromy-algia syndrome. Cochrane Database Syst Rev. 2007;4Google Scholar
  9. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthr Rheum. 1996;26: 605–11CrossRefGoogle Scholar
  10. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry. 2004;9:730–1PubMedCrossRefGoogle Scholar
  11. Buskila D. Genetics of chronic pain states. Best Pract Res Clin Rheumatol. 2007;21:535–47PubMedCrossRefGoogle Scholar
  12. Cohen ML, Quintner J. Fibromyalgia syndrome: a problem of tautology. Lancet 1993;342:906–9PubMedCrossRefGoogle Scholar
  13. Drewes AM, Svendsen L. Quantification of alpha-EEG activity during sleep in fibromyalgia: a study based on ambulatory sleep monitoring. J Musculoskel Pain. 1994;2:33–53CrossRefGoogle Scholar
  14. Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum. 1986;29:1522–6PubMedCrossRefGoogle Scholar
  15. Fukuda K, et al Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA 1998;280:981–8PubMedCrossRefGoogle Scholar
  16. Fukuda K, et al An epidemiologic study of fatigue with relevance for the chronic fatigue syndrome. J Psychiatr Res. 1997;31:19–29PubMedCrossRefGoogle Scholar
  17. Geisser ME, et al The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain. 2007;11:202–07PubMedCrossRefGoogle Scholar
  18. Gerster JC, Hadj-Djilani A. Hearing and vestibular abnormalities in primary fibrositis syndrome. J Rheumatol. 1984;11:678–80PubMedGoogle Scholar
  19. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyal-gia syndrome. JAMA 2004;292:2388–95PubMedCrossRefGoogle Scholar
  20. Goldenberg D, Mayskiy M, Mossey C, et al A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852–59PubMedCrossRefGoogle Scholar
  21. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromy-algia. Arthritis Rheum. 2002;46:1333–43PubMedCrossRefGoogle Scholar
  22. Granges G, Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum. 1993;36:642–6PubMedCrossRefGoogle Scholar
  23. Granges G, Zilko P, Littlejohn GO. Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J Rheumatol. 1994;21:523–29PubMedGoogle Scholar
  24. Hadler NM. If you have to prove you are ill, you can't get well. The object lesson of fibromyalgia. Spine 1996;21:2397–400PubMedCrossRefGoogle Scholar
  25. Harris R, Sundgren P, Pang Y, et al Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum. 2008;58:903–7PubMedCrossRefGoogle Scholar
  26. Hudson JI, Hudson MS, Pliner LF, et al Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatr. 1985;142:441–6PubMedGoogle Scholar
  27. Hudson JI, Goldenberg DL, Pope HGJ, et al Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1993;92: 363–7CrossRefGoogle Scholar
  28. Kato K, Sullivan PF, Evengard B, Pedersen NL. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med. 2006a;166:1649–54CrossRefGoogle Scholar
  29. Kato K, Sullivan PF, Evengard B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum. 2006b; 54:1682–6CrossRefGoogle Scholar
  30. Kim H, Neubert JK, San Miguel A, et al Genetic influence on variability in human experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004;109:488–96PubMedCrossRefGoogle Scholar
  31. McDermid AJ, Rollman GB, McCain GA. Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain 1996;66: 133–44PubMedCrossRefGoogle Scholar
  32. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrosi-tis syndrome” and healthy subjects. Psychosomatic Med. 1975; 37:341–51Google Scholar
  33. Offenbaecher M, et al Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42:2482–8PubMedCrossRefGoogle Scholar
  34. Older SA, et al The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlations with insulin-like growth factor I. J Rheumatol 1998;25: 1180–6PubMedGoogle Scholar
  35. Peleg R, et al Characteristics of fibromyalgia in Muslim Bedouin women in a primary care clinic. Semin Arthritis Rheum. 2008;37(6): 398–402PubMedCrossRefGoogle Scholar
  36. Petzke F, et al Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 2001;28:2568–69PubMedGoogle Scholar
  37. Pope HGJ, Hudson JI. A Supplemental interview for forms of “affective spectrum disorder”. International Journal of Psychiatry in Medicine 1991; 21(3): 205–32PubMedCrossRefGoogle Scholar
  38. Raspe H. [Rheumatism epidemiology in Europe]. Soz Praventivmed. 1992;37:168–78PubMedCrossRefGoogle Scholar
  39. Tan EM, et al Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–11PubMedCrossRefGoogle Scholar
  40. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007;55:377–91PubMedCrossRefGoogle Scholar
  41. Vitton O, Gendreau M, Gendreau J, et al A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):S27–35PubMedCrossRefGoogle Scholar
  42. White KP, Nielson WR, Harth M, et al Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47:260–5PubMedCrossRefGoogle Scholar
  43. White KP, Thompson J. Fibromyalgia syndrome in an Amish community: a controlled study to determine disease and symptom prevalence. J Rheumatol. 2003;30:1835–40PubMedGoogle Scholar
  44. Williams DA, Cary MA, Glazer LJ, et al Randomized controlled trial of CBT to improve functional status in fibromyalgia. Arthritis Rheum. 2000;43:S210Google Scholar
  45. Wolfe F, Ross K, Anderson J, et al Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151–6PubMedGoogle Scholar
  46. Yunus MB Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008;37(6):339–52Google Scholar
  47. Yunus MB, Inanici F, Aldag JC, et al Fibromyalgia in men: comparison of clinical features with women. J Rheumatol. 2000;27:485–90PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Daniel Clauw
    • 1
  • Don L. Goldenberg
    • 2
  1. 1.Medicine and Psychiatry, Chronic Pain and Fatique Research CenterUniversity of MichiganLobby M. Ann ArborUSA
  2. 2.Newton-Wellesley Hospital NewtonUSA

Personalised recommendations